Cargando…

Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis

BACKGROUND: Gynecologic oncologists should be aware of the option of conception through IVF/PGT-M for families with high BRCA related morbidity or mortality. Our objective was to investigate the cost-effectiveness of preimplantation genetic testing for selection and transfer of BRCA negative embryo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michaan, Nadav, Leshno, Moshe, Cohen, Yoni, Safra, Tamar, Peleg-Hasson, Shira, Laskov, Ido, Grisaru, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499576/ https://www.ncbi.nlm.nih.gov/pubmed/34620184 http://dx.doi.org/10.1186/s12958-021-00827-9

Ejemplares similares

Cost–Utility Analysis of Open Radical Hysterectomy Compared to Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer
por: Michaan, Nadav, et al.
Publicado: (2023)

Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?
por: Stern, Tomer, et al.
Publicado: (2021)

Effects of the COVID-19 pandemic on timely care for extrauterine pregnancies: A retrospective analysis
por: Anteby, Matan, et al.
Publicado: (2021)

Successful pregnancy following transfer of frozen-thawed embryos in a patient with pseudomyxoma peritonei who underwent peritonectomy and bilateral oophorectomy
por: Laskov, Ido, et al.
Publicado: (2012)

OTHR-03. Brain Metastasis Among Ovarian Cancer Patients
por: Limon, Dror, et al.
Publicado: (2021)

Knowledge is power? Cervical cancer prevention in female OB/GYNs compared to other female physicians
por: Hershkovitz, Gal, et al.
Publicado: (2023)

Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?
por: Laot, Lucie, et al.
Publicado: (2022)

Rapid Implementation of Telemedicine During the COVID‐19 Pandemic: Perspectives and Preferences of Patients with Cancer
por: Hasson, Shira Peleg, et al.
Publicado: (2021)

Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis
por: Peleg Hasson, Shira, et al.
Publicado: (2022)

Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer
por: Deshet-Unger, Naamit, et al.
Publicado: (2022)

Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation
por: Ramos, Marcelo Cristiano de Azevedo, et al.
Publicado: (2018)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Kambô-Induced Systemic Inflammatory Response: A Case Report of Acute Disease Progression of Cholangiocarcinoma
por: Peleg Hasson, Shira, et al.
Publicado: (2021)

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
por: Pataky, Reka, et al.
Publicado: (2013)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis
por: Julian-Reynier, Claire, et al.
Publicado: (2012)

Managing BRCA Mutation Carriers in China: Reply
por: Kwong, Ava, et al.
Publicado: (2010)

Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers
por: Paolino, Giovanni, et al.
Publicado: (2022)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis
por: Shlomai, Amir, et al.
Publicado: (2021)

Aromatase expression is increased in BRCA1 mutation carriers
por: Chand, Ashwini L, et al.
Publicado: (2009)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

The Effects of Surgical Approaches and Enhanced Recovery Protocols on the Cost Effectiveness of Radical Cystectomy
por: Kord, Eyal, et al.
Publicado: (2022)

Reciprocal Translocation Carrier Diagnosis in Preimplantation Human Embryos
por: Hu, Liang, et al.
Publicado: (2016)

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay
por: Baert, Annelot, et al.
Publicado: (2017)

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2019)

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2005)

Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
por: Ponder, B
Publicado: (2000)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_u4vsj8hagqmlknc75j8eisknl7